Sundaram Preethi sold (to issuer) $1.7M of CPRX
Sundaram Preethi (Chief Strategy Officer) sold (to issuer) 54,804 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 ($1.73M total) on 2026-07-15.
How this was made
The 30-second read
Why it matters
The newest fact is the specific insider sale to the issuer: 54,804 shares at $31.50, total $1.73M, with holdings reduced to 0 shares.
Market read
Traders may note insider selling, but there is no accompanying fundamental update in the filing text.
What to watch
No 10b5-1 plan is indicated, but the filing code D (sale to issuer) often reflects structured corporate actions rather than discretionary selling.
Background
The article is an SEC Form 4 insider transaction disclosure for Catalyst Pharmaceuticals (CPRX).
Ticker impact
Catalyst Pharmaceuticals insider Sundaram Preethi sold 54,804 shares to the issuer at $31.50 on 2026-07-15, leaving 0 shares.
Limited near-term impact; any effect is likely sentiment-only unless follow-on filings indicate broader selling.
Form 4 provides transaction details but does not disclose new company fundamentals, guidance, or regulatory/clinical events. The sale size is moderate and the filing is typically not a standalone driver of price.
Market effects
Minimal; single insider transaction in a biotech does not materially change sector risk.
None.
None.
Counterpoint
The sale could be mechanical (issuer buyback participation or planned liquidity) and not a bearish signal.
Key entities
- issuerCatalyst Pharmaceuticals, Inc.
CPRX, the company whose insider transaction is disclosed on Form 4.
- insiderSundaram Preethi
Chief Strategy Officer who sold shares to the issuer.